{"id":451118,"date":"2026-05-29T12:57:08","date_gmt":"2026-05-29T12:57:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/451118\/"},"modified":"2026-05-29T12:57:08","modified_gmt":"2026-05-29T12:57:08","slug":"4basebio-launches-high-performance-enzymatic-ssdna-platform-to-accelerate-next-generation-gene-editing","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/451118\/","title":{"rendered":"4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing"},"content":{"rendered":"<p>4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.<\/p>\n<p>Built on a proprietary enzymatic manufacturing process, the platform provides biopharma with high-purity, long-form ends protected ssDNA templates, designed to overcome critical manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, enabling large-scale, clinically viable therapeutics.<\/p>\n<p>With the growth of gene editing and with a particular need for complex &#8220;knock-in&#8221; applications, the demand for longer, purer and safer DNA templates has increased exponentially. 4basebio&#8217;s ssDNA offering enables the production of constructs up to 10,000 nucleotides with protected ends, ensuring stability, reduced immunogenicity and a cleaner path to clinical manufacturing.<\/p>\n<p>The technical advantages of the platform will be showcased at the upcoming American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting in Boston, MA. Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will deliver a presentation titled &#8220;An enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing&#8221; on 13 May at 9:00 AM EDT.<\/p>\n<p>The launch of our ssDNA platform marks a pivotal milestone in our mission to provide the foundational tools for genomic medicine and personalized therapies.\u00a0By replacing legacy chemical synthesis with our scalable, cell-free enzymatic approach, we are empowering our partners to design therapies without the traditional constraints of length or sequence complexity. We are not just providing DNA; we are enhancing the reliability and safety profile required for life-changing therapeutics.&#8221;<\/p>\n<p style=\"text-align: right;\">Amy Walker, CEO, 4basebio<\/p>\n<p>&#8220;For too long, researchers have been forced to choose between the high toxicity of double-stranded DNA or the severe length limitations of chemically synthesized oligonucleotides,&#8221; said Amine Bouchareb. &#8220;Our enzymatic platform eliminates this compromise.&#8221;<\/p>\n<p>&#8220;At ASGCT, I look forward to presenting data that demonstrates how our long-form ssDNA constructs significantly enhance Homology Directed Repair (HDR) gene editing efficiency while maintaining superior cell viability in sensitive primary cell types. This technology is the bridge between discovery-phase editing and large-scale clinical success.&#8221;<\/p>\n<p>This announcement contains inside information for the purposes of Article 7 of EU Regulation 596\/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019\/310.<\/p>\n","protected":false},"excerpt":{"rendered":"4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch&hellip;\n","protected":false},"author":2,"featured_media":14938,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[3033,6956,55,4640,2286,1428,111,139,99275,69,145,20624],"class_list":["post-451118","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-cell","tag-crispr","tag-dna","tag-gene","tag-genetic","tag-manufacturing","tag-new-zealand","tag-newzealand","tag-nucleic-acid","tag-nz","tag-technology","tag-therapeutics"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/451118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=451118"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/451118\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/14938"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=451118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=451118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=451118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}